Table 1.

Dose groups—lymphodepletion and cell doses

Dose group	Lymphodepleting chemotherapy	Transduced ADP-A2M10 (range)	Patient ID
1	Cyclophosphamide 1800 mg/m2/day on days −7 and –6	0.1×109 (0.08×109–0.12×109)	1–5
2	Cyclophosphamide 600 mg/m2/day and fludarabine 30 mg/m2/day on days –7, –6, and –5	1.0×109 (0.5×109–1.2×109)	6–8
3	Cyclophosphamide 600 mg/m2/day on days –7, –6, and –5, and fludarabine 30 mg/m2/day on days –7, –6, –5, and –4	5.0×109 (1.2×109–6×109)	9–10
Expansion group	Cyclophosphamide 1800 mg/ m2/day on days –3 and –2, and fludarabine 30 mg/m2/day on days –5, –4, –3, and –2	5.0×109 (1.2×109–15×109)	9*
	Cyclophosphamide 600 mg/m2/day on days –7, –6, and –5, and fludarabine 30 mg/m2/day on days –7, –6, –5, and –4	5.0×109 (1.2×109–15×109)	11

*One patient (patient 9) received a second infusion at this schedule of cyclophosphamide and fludarabine and ADP-A2M10.

ID, identifier.